National Bank of Canada FI Cuts Stock Holdings in Bausch Health Companies Inc. (NYSE:BHC)

National Bank of Canada FI lessened its position in Bausch Health Companies Inc. (NYSE:BHC) by 0.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,649,539 shares of the company’s stock after selling 12,185 shares during the quarter. National Bank of Canada FI owned about 4.34% of Bausch Health Companies worth $121,751,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in BHC. Goldentree Asset Management LP boosted its position in Bausch Health Companies by 19.6% during the third quarter. Goldentree Asset Management LP now owns 23,987,462 shares of the company’s stock worth $197,177,000 after acquiring an additional 3,931,234 shares during the last quarter. Nomura Holdings Inc. increased its holdings in shares of Bausch Health Companies by 67.7% in the third quarter. Nomura Holdings Inc. now owns 18,086,000 shares of the company’s stock valued at $148,667,000 after purchasing an additional 7,303,015 shares during the last quarter. Hudson Bay Capital Management LP lifted its position in Bausch Health Companies by 35.3% during the third quarter. Hudson Bay Capital Management LP now owns 11,500,000 shares of the company’s stock worth $94,530,000 after buying an additional 3,000,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in Bausch Health Companies by 1.6% during the third quarter. Vanguard Group Inc. now owns 11,487,768 shares of the company’s stock worth $94,429,000 after buying an additional 175,489 shares during the last quarter. Finally, Mizuho Markets Americas LLC purchased a new stake in Bausch Health Companies in the 3rd quarter valued at $57,540,000. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Companies Stock Down 3.3 %

BHC traded down $0.27 on Friday, hitting $7.82. The company had a trading volume of 3,396,646 shares, compared to its average volume of 3,868,373. The company’s fifty day moving average price is $9.26 and its 200 day moving average price is $8.21. Bausch Health Companies Inc. has a 1 year low of $5.57 and a 1 year high of $11.46.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.14. Bausch Health Companies had a negative net margin of 5.07% and a negative return on equity of 8,504.35%. The business had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same period last year, the business earned $1.02 earnings per share. The business’s revenue for the quarter was up 9.8% on a year-over-year basis. On average, sell-side analysts forecast that Bausch Health Companies Inc. will post 3.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on BHC shares. Jefferies Financial Group reduced their price target on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Royal Bank of Canada cut their price target on shares of Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating for the company in a report on Tuesday, April 23rd. Finally, Piper Sandler lifted their price target on shares of Bausch Health Companies from $7.00 to $9.00 and gave the company a “neutral” rating in a research report on Monday, April 29th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $11.33.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.